Robin Toft

CEO - Cancer Warrior - Supporter of Cancer Research & Women’s Health - Philanthropist- Author WE CAN & Ignite Your Board Career.

📍 United States🔄 Updated September 2026💼 4 investments📅 6 years investing🗓 Last invested Oct 2024
VC🌍 United States
4
Total investments
0
Early stage
1
Mid stage
0
Late stage
6y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Impact Investor & LP
Oct 2024
How Women Invest is a venture firm, and sister entity to How Women Lead, a professional network of over 24,000 women. We see that female founders are a force to be reckoned with and are part of an untapped venture capital landscape. We invest in U.S. based, female-led and female-majority owned companies in most industry sectors. With 40% of companies founded by women, generating 26% greater returns, and yet only 2% of venture backing, How Women Invest focuses at the intersection of this opportunity to create ecosystem change. To learn more about the firm: www.howwomeninvest.com and info@howwomeninvest.com.
Experience · 8 entries
All (8)
Investments (4)
Founder (2)
Board (3)
2024
Impact Investor & LP
Oct 2024
How Women Invest is a venture firm, and sister entity to How Women Lead, a professional network of over 24,000 women. We see that female founders are a force to be reckoned with and are part of an untapped venture capital landscape. We invest in U.S. based, female-led and female-majority owned companies in most industry sectors. With 40% of companies founded by women, generating 26% greater returns, and yet only 2% of venture backing, How Women Invest focuses at the intersection of this opportunity to create ecosystem change. To learn more about the firm: www.howwomeninvest.com and info@howwomeninvest.com.
Board Member
Jan 2024
Curebound is a San Diego-based 501c3 philanthropic organization that raises and invests strategic funding into innovative cancer research projects aimed at accelerating new discoveries to viable options for patients who need them today. Uniting two highly respected local organizations – Padres Pedal the Cause and the Immunotherapy Foundation under one banner, Curebound has collectively raised over $37 million to fund more than 123 collaborative cancer research initiatives across San Diego’s exceptional research institutions including: UC San Diego Health, Rady Children’s Hospital, Salk Institute, Sanford Burnham Prebys, La Jolla Institute for Immunology and Scripps Research. Over the next decade, Curebound is committed to investing $100 million into game-changing cancer research in to improve the lives of patients and accelerate research into cures. Under the expert leadership of the Scientific Advisory Board, Curebound seeks out the most promising areas of opportunity for research across these five pillars: • Prevention and diagnostic tools • Novel approaches and new therapeutic platforms • Immunotherapies and personalized vaccines • Addressing cancer disparities • Pediatric cancers Curebound is founded on the deeply-held belief that cures are possible and a vision of a world without cancer. We invite you to learn more and connect with us at curebound.org
2020
Board Member
Oct 2020
To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions that matter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond.
Board Member
Jun 2020
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
Founder, CEO, Author, Speaker, Connector
Jun 2020
A community of women, men and companies committed to solving the talent crisis, one woman at a time.
Show all 8 entries ↓
Investment activity
2020–2024 · 4 investments
2020220242
Recent (last 2 years)Earlier